<DOC>
	<DOCNO>NCT03093961</DOCNO>
	<brief_summary>The objective pilot study evaluate safety performance implant IASD® System II Heart Failure patient reduce ejection fraction elevate leave sided filling pressure , remain symptomatic despite Guideline Directed Medical Therapy ( GDMT ) .</brief_summary>
	<brief_title>Reduce LAP-HFREF TRIAL</brief_title>
	<detailed_description>The intended clinical indication IASD System II reduction elevate LAP patient symptomatic heart failure reduce ejection fraction , despite appropriate medical management . The implant design center barrel opening , set elevate LAP , allow leave right flow . Since many symptom patient experience believe due elevate LAP , IASD System II potential significantly reduce symptom improve quality life patient otherwise limited treatment option . The study design prospective , non-randomized , single-arm feasibility trial . This study implant 10 subject . The population include heart failure patient reduce ejection fraction , elevate leave sided filling pressure , remain symptomatic despite GDMT , include optimal dos recommend pharmaceutical treatment , surgical , device intervention ( ) ( CRT , AICD , reduction MRI ) . After analysis 1 month result ( include baseline 1 month Core laboratory echocardiographic hemodynamic data ) first 5 implanted patient , decision make implant additional 5 patient ,</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>1 . Chronic symptomatic Heart Failure ( HF ) document follow : 1 . New York Heart Association ( NYHA ) Class III/ambulatory class IV symptom ( Paroxysmal nocturnal dyspnea , Orthopnea , Dyspnea mild moderate exertion ) screen visit , sign ( e.g . rales post cough , Chest xray demonstrate pulmonary congestion , ) within past 12 month ; AND 2 . One hospital admission HF major component hospitalization within 12 month prior study entry ( transient heart failure context myocardial infarction qualify ) , one emergency department visit IV treatment HF within 12 month prior study entry 2 . Ongoing stable GDMT HF ( Class I , IIa recommendation ) accord 2016 ACC/AHA Guidelines management Heart Failure ( significant change [ &gt; 100 % increase 50 % decrease ] , exclude diuretic dose change minimum 3 month prior screen ) , expect maintain without change 6 month 3 . Age ≥ 18 year old 4 . Reduced Left ventricular ejection fraction 20 % 40 % documented echocardiography , radio nuclide ventriculography , MRI within past 3 month 5 . Elevated leave atrial pressure gradient compare right atrial pressure ( RAP ) document : . Resting end expiratory PCWP ≥ 18 mmHg , great RAP ≥ 5 mmHg 6 . Subject informed nature study , agree provision provide write informed consent , approve IRB 7 . Subject willing comply clinical investigation procedure agree return require followup visit , test , exams 1 . Patients receive GDMT specify reason 2 . NTPro BNP &lt; 100 pmol/L ( sinus rhythm ) , &lt; 300 pmol/L ( atrial fibrillation ) 3 . Myocardial infarction ( MI ) and/or percutaneous cardiac intervention within past 3 month ; CABG past 3 month , current indication coronary revascularization 4 . Cardiac Resynchronization Therapy initiate within past 3 month 5 . Automated Implantable Cardioverter Defibrillator ( AICD ) place within past 3 month 6 . Severe heart failure define follow : 1 . ACC/AHA/ESC Stage D heart failure , Nonambulatory NYHA Class IV HF ; 2 . Cardiac Index &lt; 2.0 L/min/m2 3 . Requiring inotropic infusion ( continuous intermittent ) within past 3 month . 4 . Listed transplant wait list 7 . Ability perform 6 minute walk Test &gt; 600m 8 . Known clinically significant unrevascularized coronary artery disease , define : epicardial coronary artery stenosis associate angina evidence coronary ischemia . 9 . History stroke , transient ischemic attack ( TIA ) , deep vein thrombosis ( DVT ) , pulmonary embolus within past 6 month recurrent DVT/pulmonary embolus 10 . Presence significant valve disease define echocardiography : 1 . Mitral valve regurgitation define grade &gt; 2+ MR 2 . Tricuspid valve regurgitation define grade &gt; 2+ TR ; 3 . Aortic valve disease define ≥ 2+ AR moderate AS 11 . Subject contraindicate receive either dual antiplatelet therapy warfarin analogue ; document coagulopathy 12 . Atrial fibrillation rest HR &gt; 100 BPM 13 . Arterial Oxygen saturation &lt; 95 % room air 14 . Significant hepatic impairment define 3X upper limit normal transaminase , total bilirubin , alkaline phosphatase ; Hepatic cirrhosis ; Hypoalbuminemia 15 . Resting RAP &gt; 14 mmHg 16 . Right ventricular dysfunction , define 1 . More mild RV dysfunction determine TTE : OR 2 . TAPSE &lt; 1.4 cm : OR 3 . RV volume ≥ LV volume echo estimate ; OR 4 . Evidence RV dysfunction define echo RV fractional area change &lt; 35 % 17 . Evidence pulmonary hypertension PVR ≥4 Woods Units 18 . Chronic pulmonary disease require continuous home oxygen , OR significant chronic pulmonary disease define FEV1 &lt; 1L . 19 . Currently participate investigational drug device study may interfere conduct outcome study . 20 . Life expectancy le 12 month noncardiovascular reason 21 . Echocardiographic evidence intracardiac mass , thrombus vegetation 22 . Known suspected allergy nickel 23 . Women child bear potential 24 . Currently require dialysis ; eGFR &lt; 25ml/min 25 . Systolic blood pressure &gt; 170 mmHg despite appropriate medical management 26 . Subjects exist Atrial Septal Defects . Subjects Patent Foramen Ovale ( PFO ) , elevate filling pressure despite PFO allow 27 . Subjects immunosuppression systemic steroid treatment 28 . In opinion investigator , subject appropriate candidate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>